Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Perspective: Treatment for Disease Modification in Chronic Neurodegeneration
Thomas Müller, Bernhard K. Mueller, Peter Riederer
Cells (2021) Vol. 10, Iss. 4, pp. 873-873
Open Access | Times Cited: 18

Showing 18 citing articles:

A novel electrochemical sensor based on collaborative performance enhancement of hybrid Acid Orange 10 polymer/zirconium nanoparticles for first voltammetric determination of Istradefylline in plasma
Marwa F. B. Ali, Ibrahim A. Darwısh, Noha M. Hosny
Microchemical Journal (2025), pp. 112911-112911
Closed Access | Times Cited: 2
The Pharmacological Potential of Adenosine A2A Receptor Antagonists for Treating Parkinson’s Disease
Akihisa Mori, Jiang‐Fan Chen, Shinichi Uchida, et al.
Molecules (2022) Vol. 27, Iss. 7, pp. 2366-2366
Open Access | Times Cited: 36
Blood-based biomarker in Parkinson’s disease: potential for future applications in clinical research and practice
Lars Tönges, Carsten Buhmann, Stephan Klebe, et al.
Journal of Neural Transmission (2022) Vol. 129, Iss. 9, pp. 1201-1217
Open Access | Times Cited: 36
Aminoadamantanes: from treatment of Parkinson’s and Alzheimer’s disease to symptom amelioration of long COVID-19 syndrome?
Thomas Müller, Peter Riederer, W. Kuhn
Expert Review of Clinical Pharmacology (2023) Vol. 16, Iss. 2, pp. 101-107
Closed Access | Times Cited: 14
Mesenchymal stromal/stem cells from perinatal sources: biological facts, molecular biomarkers, and therapeutic promises
Mohammed Z. Allouh, Syed Faizan Ali Rizvi, Ali Al Bshabshe, et al.
Stem Cell Research & Therapy (2025) Vol. 16, Iss. 1
Open Access
Neuroinflammatory response after subarachnoid hemorrhage: A review of possible treatment targets
Xiuwen Fu, Chenlu Li, Hongru Jiang, et al.
Clinical Neurology and Neurosurgery (2025), pp. 108843-108843
Open Access
The role of istradefylline in the Parkinson’s disease armamentarium
Thomas Müller
Expert Opinion on Pharmacotherapy (2023) Vol. 24, Iss. 7, pp. 863-871
Closed Access | Times Cited: 11
DNL151, DNL201, and BIIB094: experimental agents for the treatment of Parkinson’s disease
Thomas Müller
Expert Opinion on Investigational Drugs (2023) Vol. 32, Iss. 9, pp. 787-792
Closed Access | Times Cited: 6
What are the main considerations when prescribing pharmacotherapy for Parkinson’s disease?
Thomas Müller
Expert Opinion on Pharmacotherapy (2022) Vol. 23, Iss. 7, pp. 745-750
Open Access | Times Cited: 10
The vicious circle between homocysteine, methyl group-donating vitamins and chronic levodopa intake in Parkinson’s disease
Thomas Müller, Peter Riederer
Journal of Neural Transmission (2023) Vol. 131, Iss. 6, pp. 631-638
Closed Access | Times Cited: 4
Associations between multiple neurological biomarkers and distal sensorimotor polyneuropathy: KORA F4/FF4 study
Christian Herder, Barbara Thorand, Alexander Strom, et al.
Diabetes/Metabolism Research and Reviews (2024) Vol. 40, Iss. 5
Closed Access | Times Cited: 1
AMPK activators for the prevention and treatment of neurodegenerative diseases
Natalie R. Neumann, David C. Thompson, Vasilis Vasiliou
Expert Opinion on Drug Metabolism & Toxicology (2021) Vol. 17, Iss. 10, pp. 1199-1210
Closed Access | Times Cited: 10
Curcumin- β-Cyclodextrin Molecular Inclusion Complex: A Water- Soluble Complex in Fast-dissolving Tablets for the Treatment of Neurodegenerative Disorders
Sruthi Laakshmi Mugundhan, Purushothaman Balasubramaniyan, Damodharan Narayanasamy, et al.
Pharmaceutical Nanotechnology (2024) Vol. 12, Iss. 4, pp. 365-377
Closed Access
Clinicians’ viewpoints on current paradigms of care and research in Parkinson’s disease
Thomas Müller, Carsten Buhmann, Martin Delf, et al.
Journal of Neural Transmission (2024) Vol. 131, Iss. 12, pp. 1455-1462
Closed Access
Perspective: cell death mechanisms and early diagnosis as precondition for disease modification in Parkinson’s disease: are we on the right track?
Thomas Müller
Expert Review of Molecular Diagnostics (2022) Vol. 22, Iss. 4, pp. 403-409
Closed Access | Times Cited: 1
Perspective: Is a Closer Interaction between Experimental and Clinical Research Paradigms in Chronic Neurodegeneration, Such as Parkinson’s Disease, Necessary Again?
Thomas Müller
Cells (2022) Vol. 12, Iss. 1, pp. 157-157
Open Access | Times Cited: 1
Memantine for Treatment of Dementia
Thomas Müller, W. Kuhn
Springer eBooks (2022), pp. 1-9
Closed Access
Memantine for Treatment of Dementia
Thomas Müller, W. Kuhn
Springer eBooks (2022), pp. 2723-2731
Closed Access
Page 1

Scroll to top